drugset / Trial / NCT00305669
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
Phase 1
Completed
24 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer. PURPOSE: This clinical trial is studying how well giving GM-CSF before surgery works in treating patients with localized prostate cancer.
Timeline
- Start
- 2006-07
- Primary completion
- 2011-01
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | 125 ug/m2 | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |